Inactive

January 17, 2024 - Amendment 02: This amendment revises the Basis of Estimate and and Tech & Management templates. An updated FAQ document is also posted. January 10, 2024 - Updated FAQs posted. Decem... January 17, 2024 - Amendment 02: This amendment revises the Basis of Estimate and and Tech & Management templates. An updated FAQ document is also posted. January 10, 2024 - Updated FAQs posted. December 27, 2023 - Amendment 01: This amendment updates the eligiility for Federally Funded Research and Development Centers (FFRDCs) and Government entities. This amendment also adds additional instructions for the Basis of Estimate (BOE). Volume 1 proposals remain due on January 26, 2024. The Advanced Research Projects Agency for-Health (ARPA-H) is soliciting proposals for the Resilient Extended Automatic Cell Therapies (REACT) program using the Master Announcement Instruction (MAI) solicitation strategy. For more information, please refer to the attached ARPA-H-MAI-24-01, which aims to provide proposers with the ability to scale the level of effort that they spend developing proposal materials with the magnitude of the effort they plan to propose. The MAI introduces a tiered approach to proposal submission for small scale (BIT / BYTE), mid-scale (KILO/MEGA), and large scale (GIG/TERA) efforts. The REACT solicitation described below is soliciting a Module Announcement at the large-scale GIG Module category level. All awards will be made in the form of an Other Transaction (OT). Specifically, ARPA-H is soliciting innovative proposals for research and development (R&D) in therapeutic development and affordability and improving the way patients manage their own health. Currently many therapeutics are ineffective, not because they are medically unsound, but because of the barriers faced by patients who need them. Limited access and high costs block many patients from benefiting from the newest treatment regimes. Moreover, many acute and lifelong diseases significantly burden patients with continuous management of their health through pills, injections, blood draws, or even invasive surgery. This burden often leads to low treatment fidelity and poor health outcomes for the patient. Improving health and wellness requires simultaneous resolution of limitations in access and affordability.

Inactive

UPDATE 12/4/23: Abstracts are now being accepted. Please follow the instructions in the Special Announcement ARPA-H-SN-24-02. UPDATE 11/30/23: Abstracts will be due on December 7, 2023. Abstracts subm... UPDATE 12/4/23: Abstracts are now being accepted. Please follow the instructions in the Special Announcement ARPA-H-SN-24-02. UPDATE 11/30/23: Abstracts will be due on December 7, 2023. Abstracts submissions will not be accepted until the final Module Announcement has been posted on SAM.gov. The Advanced Research Projects Agency for-Health (ARPA-H) is soliciting proposals for the Resilient Extended Automatic Cell Therapies (REACT) program using the Master Announcement Instruction (MAI) solicitation strategy. For more information, please refer to the attached ARPA-H-MAI-24-01, which aims to provide proposers with the ability to scale the level of effort that they spend developing proposal materials with the magnitude of the effort they plan to propose. The MAI introduces a tiered approach to proposal submission for small scale (BIT / BYTE), mid-scale (KILO/MEGA), and large scale (GIG/TERA) efforts. The REACT solicitation described below is soliciting a Module Announcement at the large-scale GIG Module category level. All awards will be made in the form of an Other Transaction (OT). Specifically, ARPA-H is soliciting innovative proposals for research and development (R&D) in therapeutic development and affordability and improving the way patients manage their own health. Currently many therapeutics are ineffective, not because they are medically unsound, but because of the barriers faced by patients who need them. Limited access and high costs block many patients from benefiting from the newest treatment regimes. Moreover, many acute and lifelong diseases significantly burden patients with continuous management of their health through pills, injections, blood draws, or even invasive surgery. This burden often leads to low treatment fidelity and poor health outcomes for the patient. Improving health and wellness requires simultaneous resolution of limitations in access and affordability.